A new study suggests that antibodies produced by vaccinia-based vaccines may neutralize the Monkeypox virus, suggesting potential cross-protection against new threats.
The findings emphasize VisMederi’s capability to aid in vaccine development and research efforts for the ongoing public health crisis related to monkeypox. Vismederi has evaluated and validated the assays for detecting functional antibodies.
For the complete article, visit the PubMed website: https://pubmed.ncbi.nlm.nih.gov/37415699/
